CD274 and lung cancer: Similarly, the m^6A-modified circIGF2BP3 in non–small cell lung cancer (NSCLC) enhances PD-L1 deubiquitination and stabilization through the recruitment of OTUB1, dampening CD8+ T cell responses and contributing to resistance against PD-1 blockade (34, 46).